rs1341162 — CYP2C8

CYP2C8 Intron 5 — A Haplotype Tag with Drug and Bone Consequences

CYP2C8 is one of the body's principal drug-processing enzymes, responsible for clearing roughly 5% of all commonly prescribed medications. Its substrates span remarkably diverse drug classes: the antidiabetics repaglinide and rosiglitazone, the chemotherapy agent paclitaxel, the antimalarial amodiaquine, and several NSAIDs including ibuprofen. Beyond drug metabolism, CYP2C8 converts arachidonic acid into [epoxyeicosatrienoic acids (EETs) | lipid signaling molecules with vasodilating, anti-inflammatory, and bone-protective properties], making CYP2C8 activity relevant far outside the pharmacy.

rs1341162 sits in intron 5 of CYP2C8 on chromosome 10 (GRCh38 position 95,050,855) and does not directly alter the enzyme's amino acid sequence. Its significance lies in what it tags: a broader intronic haplotype block that cosegregates with altered CYP2C8 expression and activity.

The Mechanism

The T allele at rs1341162 travels together with the T allele at rs1934951¹¹ rs1934951
intron 8 variant; the most strongly MRONJ-associated CYP2C8 SNP and the T allele at rs1934980, forming the "TGT" haplotype first identified by Sarasquete et al., Blood 2008²² Sarasquete et al., Blood 2008
PMID 18594024. This haplotype was present in 45% of bisphosphonate-treated multiple myeloma patients who developed osteonecrosis of the jaw, compared with only 10% of controls — an odds ratio exceeding 7. The complementary "CAC" haplotype (the C allele at all three positions) was the protective common form (83% in controls vs 50% in cases).

The exact molecular mechanism by which intronic variants in this haplotype alter CYP2C8 function remains incompletely characterized. Intronic variants can affect [pre-mRNA splicing | intronic sequences contain regulatory elements that guide the spliceosome], create or destroy branch points, or alter regulatory elements recognized by RNA-binding proteins. Functional studies of related CYP2C8 intronic haplotypes (the "haplotype B" described by Rodríguez-Antona et al., 2007³³ Rodríguez-Antona et al., 2007
PMID 17923851) showed significantly increased paclitaxel 6α-hydroxylation in liver microsomes, suggesting at least some intronic variants in this region do alter expression or splicing.

The Bisphosphonate Connection

The leading hypothesis connecting CYP2C8 to [medication-related osteonecrosis of the jaw (MRONJ) | jaw bone death complicating bisphosphonate treatment in ~5% of cancer patients receiving high-dose IV therapy] is EET-mediated. CYP2C8 produces EETs from arachidonic acid, and EETs have been shown to directly suppress osteoclast formation, inhibit NF-κB and RANKL signaling in bone cells, and reduce inflammatory cytokines (TNF-α, IL-1β) that drive bone resorption (Norwood et al., 2014⁴⁴ Norwood et al., 2014
PMID 25466887). If the TGT haplotype reduces CYP2C8 activity and lowers EET output in jaw bone, it may create a permissive inflammatory environment in which the additional bone-metabolic stress of bisphosphonates — which suppress osteoclast renewal, impair angiogenesis, and trap necrotic fragments — tips into clinical necrosis.

The Evidence

The discovery study by Sarasquete et al. used 500,568 SNPs across 22 multiple myeloma cases with MRONJ and 65 matched controls; rs1341162 reached p = 6.22 × 10⁻⁶ (below the Bonferroni-corrected threshold of p = 1 × 10⁻⁷ for that array). The stronger signal came from rs1934951 (p = 1.07 × 10⁻⁶; OR 12.75), which is in strong LD with rs1341162. A replication study by Such et al. (Haematologica, 2011; PMID 21685474⁵⁵ PMID 21685474) in 79 myeloma patients could not confirm a statistically significant association, illustrating the modest statistical power of these relatively small cohorts. A meta-analysis of rs1934951 (the lead SNP in this block) found pooled OR ~3.2 across available studies, consistent with a real but attenuated effect (PMID 23171856⁶⁶ PMID 23171856).

For the drug-metabolism dimension, intronic CYP2C8 haplotypes shift paclitaxel, repaglinide, and amodiaquine pharmacokinetics in population studies, though the effect size is smaller than for the nonsynonymous CYP2C8*3 allele (rs10509681 + rs11572080). The evidence level for rs1341162 specifically is moderate — the haplotype association is replicated but the mechanistic connection remains incompletely resolved.

Practical Actions

Carriers of the TT genotype (approximately 9% globally, 4% in Europeans) carry the full dose of the risk haplotype. For patients facing bisphosphonate treatment — particularly high-dose intravenous therapy with zoledronic acid or pamidronate for multiple myeloma or bone metastases — knowledge of this variant status provides an early signal to intensify dental surveillance before starting treatment. For oncologists managing paclitaxel-based regimens, CYP2C8 haplotype status may be one factor to consider alongside the more established CYP2C8*3 genotype when calibrating dose-related neuropathy risk.

Interactions

rs1341162 is part of a broader intronic haplotype block with rs1934951 and rs1934980. Its effects compound with the nonsynonymous CYP2C8*3 allele (defined by rs11572080 and rs10509681), which reduces enzyme activity to ~50% of wild-type. Individuals carrying both the TGT intronic haplotype and one or two CYP2C8*3 alleles have the most reduced CYP2C8 capacity and, in theory, the greatest MRONJ and drug-accumulation risk.